Palvella Therapeutics (PVLA) Q3 2025 earnings summary

Executive summary

• Advanced a diversified pipeline of QTORIN-derived candidates for four rare skin diseases with no FDA-approved therapies, including microcystic lymphatic malformations, cutaneous venous malformations, angiokeratomas, and DSAP.

• Achieved key milestones: over-enrollment in Phase 3 SELVA (microcystic LM), full enrollment in Phase 2 TOIVA (cutaneous VM), and announced new programs for angiokeratomas and DSAP.

• Completed a reverse merger with Pieris Pharmaceuticals in December 2024, resulting in recapitalization and $78.9 million PIPE financing.

• Strengthened leadership with key hires in innovation, commercial, and regulatory roles.

Financial highlights

• Ended Q3 2025 with $63.6 million in cash and equivalents, supporting operations into H2 2027.

• Q3 2025 operating expenses totaled $10.2 million, driven by increased R&D and G&A costs.

• Net loss for the nine months ended September 30, 2025 was $29.0 million, with an accumulated deficit of $122.7 million.

• Projected to exit 2025 with ~$55 million in cash, sufficient for multiple data and regulatory milestones.

Outlook and guidance

• Top-line Phase 2 TOIVA data for cutaneous venous malformations expected mid-December 2025; Phase 3 SELVA data for microcystic LM expected Q1 2026.

• NDA submission for QTORIN Rapamycin in microcystic LM planned for H2 2026, with potential FDA approval in 1H 2027.

• Phase 2 trials for QTORIN rapamycin in angiokeratomas and QTORIN pitavastatin in DSAP anticipated to begin in H2 2026.

• No expectation of commercial revenue or positive operating cash flows in the next two years; additional financing may be needed for future commercialization.